Navigating Treatment Sequencing in HER2+ Metastatic Breast Cancer: Evidence-Based Approaches - Episode 4
Panelists discuss how the presence of brain metastases influences treatment decisions in HER2-positive (HER2+) breast cancer, highlighting the DESTINY-Breast12 trial demonstrating trastuzumab deruxtecan’s (T-DXd) efficacy in patients with brain metastases.
Clinical Brief: Brain Metastases in HER2+ Breast Cancer
Key Themes:
Key Points for Physicians:
Notable Insights:
Clinical Significance:
The approach to brain metastases in HER2+ breast cancer is evolving with emerging evidence of CNS activity for newer targeted agents, potentially changing the paradigm of when to screen for and how to manage brain metastases in this patient population.